NCM · Biotechnology

Alaunos Therapeutics, Inc. (TCRT) Stock

$0.80 +2.45% NCM: TCRT Healthcare

Valuation

MetricValue
Price$0.80
Market Cap$1.95M
P/E Ratio-0.42
P/B Ratio3.06
P/S Ratio667.52
EPS (TTM)$-2.20
52-Week High$4.59
52-Week Low$0.73
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-232.60%
ROA-264.51%
ROCE-622.39%
Gross Margin-63.33%
Operating Margin-1381.67%
Net Margin-1369.67%
Debt/Equity0.00
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$3.0M$0$0$0
Operating Profit$-78.0M$-35.0M$-34.0M$-5.0M$-4.0M
Net Profit$-79.0M$-38.0M$-35.0M$-5.0M$-4.0M
EPS$-53.80$-25.97$-21.97$-2.92$-2.20
Op Margin-19484.7%-1201.4%-685340.0%-48120.0%-84500.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$95.0M$65.0M$8.0M$3.0M$3.0M
Total Liabilities$37.0M$26.0M$2.0M$1.0M$1.0M
Cash$76.0M$39.0M$6.0M$1.0M$1.0M
Borrowings$30.0M$20.0M$0$0$0

Latest News

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study GlobeNewswire · Jun 29, 2026 Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers Stocktwits · May 26, 2026 Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies GlobeNewswire · May 26, 2026 Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models GlobeNewswire · May 18, 2026 Ziopharm: Q1 Earnings Snapshot Associated Press · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-61.0M$-29.0M$-30.0M$-5.0M$-3.0M
Investing Cash Flow$-7.0M$0$1.0M$0$0
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$-39.0M$-23.0M$-47.0M$-5.0M$0
Free Cash Flow$-65.0M$-29.0M$-30.0M$-5.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-0.47
FCF Yield-141.07%
Quick Ratio0.77
Interest Coverage0.00
Return 1Y-36.98%
Return 3Y-96.98%
Return 5Y-99.40%

Ownership

Insiders Held14.51%
Institutions Held6.53%
Institutions Float Held7.64%
Institutional HolderSharesReport Date
Blackrock Inc.21,3532026-03-31
Geode Capital Management, LLC22,5602026-03-31
Vanguard Fiduciary Trust Co15,4972026-03-31
Vanguard Capital Management LLC14,0632026-03-31
HRT Financial LP13,3272026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADXNAddex Therapeutics Ltd $5.89 -0.17% -0.72 $4.24M 0.00%
AIMAIM ImmunoTech Inc. $0.18 -1.75% -0.05 $7.04M 0.00%
CYCN $23.52 +0.00% -2.42 $15.73M 0.00%
IBOImpact BioMedical, Inc. $4.39 +6.81% -4.48 $37.51M 0.00%
KTTAPasithea Therapeutics Corp. $0.44 -0.56% -0.19 $14.73M 0.00%

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. is led by CEO Holger Weis, employs 1 people, headquartered in US, publicly traded since 2005.

Alaunos Therapeutics, Inc. (TCRT) stock trades at $0.80 with a market capitalization of $1.95M. The stock is valued at a price-to-earnings (P/E) ratio of -0.42, price-to-book of 3.06, price-to-sales of 667.52. Over the past 52 weeks the stock has ranged between $0.73 and $4.59, and currently trades 82.6% below its 52-week high.

On profitability, Alaunos Therapeutics, Inc. generates a return on equity (ROE) of -232.60%, return on capital employed of -622.39%, an operating margin of -1381.67%, a net profit margin of -1369.67%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1172.83 +0.28% JNJ Johnson & Johnson $260.45 +1.55% ABBV AbbVie Inc. $276.98 +1.67% MRK Merck & Company, Inc. Common Stock (new) $145.34 +2.08% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.24 +1.43% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $658.31 +0.97% AMGN Amgen Inc. $413.31 +1.44% GILD Gilead Sciences, Inc. $150.80 +2.52% ABT Abbott Laboratories $99.69 +1.21% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides